<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835664</url>
  </required_header>
  <id_info>
    <org_study_id>NL58119.068.16</org_study_id>
    <nct_id>NCT02835664</nct_id>
  </id_info>
  <brief_title>Nicotinamide Riboside and Metabolic Health</brief_title>
  <official_title>Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of 6 week Nicotinamide Riboside supplementation (1000
      mg/day) on metabolic health in healthy (pre)obese humans. The primary objective will be
      hepatic and whole body insulin sensitivity. Secondary objectives, to provide information
      about the underlying mechanism, will be muscle mitochondrial function, brown fat activity,
      ectopic lipid accumulation, energy metabolism, cardiovascular risk parameters, body
      composition and acetylcarnitine levels.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity: muscle- and liver specific</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Hyperinsulinemic euglycemic clamp: Rate of glucose disappearance (Rd) will be calculated by using tracer kinetics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle mitochondrial function (ex vivo)</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Ex vivo mitochondrial function in skeletal muscle measured by oxygen consumption in muscle fibres (muscle biopsy vastus lateralis) on lipid-derived and carbohydrate-derived substrates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ectopic lipid accumulation</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Liver and skeletal muscle lipid accumulation measured with H-MRS in vivo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brown adipose tissue activity</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Subjects will be exposed to an individualized cooling protocol, after which an 18F-FDG PET/CT scan is made</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular risk parameters</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Cardiac energy status measured with P-MRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body energy expenditure</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Sleeping metabolic rate measured during an overnight stay in a respiration chamber.
Resting metabolic rate measured with ventilated hood system, basal, during insulin stimulation (clamp) and during cold stimulation (cooling protocol BAT activity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Fat mass and fat free mass measured with a BodPod.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetylcarnitine levels</measure>
    <time_frame>6 weeks after supplementation</time_frame>
    <description>Skeletal muscle acetylcarnitine levels measured with H-MRS in vivo, before and after exercise stimulation (cycling).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obesity</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementation of Nicotinamide Riboside (Niagen) of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Supplementation of Placebo of 1000 mg/day for 6 weeks. 2 capsules in the morning together with breakfast and 2 capsules around noon together with lunch. Each capsule contains 250 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide Riboside (Niagen)</intervention_name>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Nicotinamide Riboside</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Caucasian

          -  Males and postmenopausal females

          -  Aged 45-65 years at start of the study

          -  Body mass index (BMI) 27 - 35 kg/m2

          -  Stable dietary habits (no weight loss or gain &gt;5kg in the past 3 months)

          -  Sedentary lifestyle (not more than 2 hours of sports per week)

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Active diseases (cardiovascular, diabetes, liver, kidney, cancer or other)

          -  Contra-indication for MRI

          -  Participation in earlier research or medical examination that included PET/CT scanning

          -  Alcohol consumption of &gt;2 servings per day

          -  Smoking in the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Schrauwen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlijn Remie, Msc</last_name>
    <phone>0031 43 3884596</phone>
    <email>carlijn.remie@maastrichtuniversity.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patrick Schrauwen, PhD</last_name>
    <phone>0031 43 3881502</phone>
    <email>p.schrauwen@maastrichtuniversity.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlijn Remie, Msc</last_name>
    </contact>
    <contact_backup>
      <last_name>Patrick Schrauwen, Prof.Dr.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nicotinamide Riboside</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic health</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Mitochondrial function</keyword>
  <keyword>Brown adipose tissue</keyword>
  <keyword>Energy expenditure</keyword>
  <keyword>Ectopic lipid accumulation</keyword>
  <keyword>Cardiovascular risk</keyword>
  <keyword>Acetylcarnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

